NCT05078866 — Nouscom NOUS-209 neoantigen vaccine trial
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
Registry record
| Registry ID | NCT05078866 ↗ |
|---|---|
| Lead sponsor | National Cancer Institute (NCI) |
| Collaborators | — |
| Phase | Phase 1/2 |
| Status | Active Not Recruiting |
| Indication | Colorectal Carcinoma, Lynch Syndrome |
| Enrollment | 45 participants (target) |
| Start date | 2022-11-10 |
| Primary completion | 2025-04-16 |
| Last registry update | 3 Mar 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05078866), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05078866?
NCT05078866 (Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by National Cancer Institute (NCI).
Is NCT05078866 recruiting?
As of the 2026-03-03 registry update, NCT05078866 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05078866?
The lead sponsor is National Cancer Institute (NCI).
What condition does NCT05078866 study?
The registered conditions are Colorectal Carcinoma, Lynch Syndrome. Primary completion is listed as 2025-04-16.
Are results available for NCT05078866?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05078866.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.